The X-Change Corporation Sees More Evidence of Treatment Benefits of Cannabinoids For Life Threatening Cancer Conditions

phytivaCOLORADO SPRINGS, Colo., Aug. 7, 2013 /PRNewswire/ — The X-Change Corporation (NASDAQ OTC: XCHC), a U.S. Company specializing in cannabinoid formulation-based health and wellness solutions, recognizes a Japanese report suggesting that synthetic cannabinoids, such as JWH-018, -122 and -210, may be used as cancer chemopreventive agents. In the study published by theJournal of Pharmacy and Pharmacology in August 2013 researchers from the Tokyo Metropolitan Institute of Public Health demonstrated that synthetic cannabinoids display potent anti-inflammatory activity and marked inhibition of tumor promotion by TPA in the two-stage mouse skin carcinogenesis model. This evidence suggests that X-Change Corp’s product lines, which include natural combinations of high-quality, organic cannabinoids, should yield efficacious anti-cancer properties. With each new study on the health benefits of cannabinoids, the strategic direction of X-Change Corp is reaffirmed.

X-Change Corp’s product lines continue to mature toward critical care for people suffering from life threatening diseases like cancer and HIV. The Company’s strategic research collaborations, including our strategic partners, Cannabis Science, Inc. and the medical cannabis dispensaries in legal state jurisdictions, will advance these cannabinoid-based breakthroughs in the rapidly expanding critical care market. Further, while chemotherapy and surgical treatment costs quickly rise into the hundreds of thousands of dollars per patient on an annual basis, safe, natural, and effective cannabinoid-based treatments for the same ailments are projected to cost less then ten thousands dollars per patient per annum.

Anecdotal results of self-treated patients have evidenced dramatic therapeutic results from cannabinoid-based treatments. Cannabis Science, Inc. and X-Change Corp are collaborating to document the clinical efficacy of such treatments. This is why X-Change Corp continues to believe in the value of the Company’s “Patient Resource Center” portal of its website, where anyone can learn, share, and see real time progress of cannabinoid-based treatments. The link is; click on the “Patient Resource Center” Tab at the top or middle of the page.

“We have been focusing our efforts on meeting the ever increasing market demand for natural cannabinoid-based solutions for minor to life-threatening ailments. It’s simply the right thing to do and it is a growing business opportunity. Each new scientific study or clinical trial that provides new evidence for cannabinoid based treatment efficacy supports X-Change Corp’s innovative research strategy and unique product line development,” stated Dr. Dorothy Bray, President of The X-Change Corporation, after learning of this new Japanese anti-cancer study.

About The X-Change Corporation
The X-Change Corporation is currently developing new natural cannabinoid containing products based on innovative formulations to utilize the unique and potent benefits of the cannabis and hemp plants. Medicinal properties of cannabis and hemp have been known and applied for thousands of years. With the aid of scientific research, The X-Change Corporation is translating such knowledge into development of effective cannabinoid formulation-based health and wellness solutions as well as cosmeceutical, nutraceutical, and food brands throughout the world. The Company’s health and wellness, nutritional, and cosmetics lines will address personal needs and will evolve with the introduction of new formulations and products, advancing the Company within the expanding multibillion-dollar global market.

Forward Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as “anticipate,” “seek,” intend,” “believe,” “plan,” “estimate,” “expect,” “project,” “plan,” or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based solutions. X-Change Corp. does not undertake any duty nor does it intend to update the results of these forward-looking statements.

The X-Change Corporation

Dr. Dorothy Bray, President

Investment Inquiries
Robert Kane
CFO, Sr Vp of Business Development


Tags: , , , , ,